Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

CT-996

Stage Phase 1Stale

Sponsor Carmot Australia First Pty Ltd

Route oral

Sources

registry, as of 2025-11-28Stale

https://clinicaltrials.gov/study/NCT05814107

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE1. Lead sponsor Carmot Australia First Pty Ltd. Enrollment 94. Conditions Type 2 Diabetes; Overweight or Obesity. This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).

ClinicalTrials.gov NCT05814107 protocol and results modules

Studies

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

Registry NCT05814107

Phase Phase 1

Status Completed

Enrollment 94

Start 2023-05-09

Primary completion 2025-11-07

Study completion 2025-11-07

Catalyst Primary completion. 2025-11-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part 1: CT-996 SAD Cohort 1

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 1: CT-996 SAD Cohort 2

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 1: CT-996 SAD Cohort 3, Then SAD Cohort 5

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 1: CT-996 SAD Cohort 4

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 1: CT-996 SAD Cohort 6

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 1: Placebo SAD Cohort

Population Type 2 Diabetes; Overweight or Obesity

Part 2: CT-996 MAD Cohort 1

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 2: CT-996 MAD Cohort 2

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 2: CT-996 MAD Cohort 3

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 2: Placebo MAD Cohort

Population Type 2 Diabetes; Overweight or Obesity

Part 3: CT-996 MD T2DM Cohort 1

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 3: CT-996 MD T2DM Cohort 2

Comparator placebo

Population Type 2 Diabetes; Overweight or Obesity

Part 3: Placebo MD T2DM Cohort

Population Type 2 Diabetes; Overweight or Obesity